Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment
The approval makes Biocon's pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.